Cynata Therapeutics Limited (AU:CYP) has released an update.
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Cynata Therapeutics Limited has requested a trading halt on its securities on the ASX, pending an announcement about the results of its Phase 1 clinical trial for diabetic foot ulcers. The halt will remain until the announcement is made or normal trading resumes on December 6, 2024. This development is likely to attract investor attention as Cynata continues to advance its stem cell therapy platform.
For further insights into AU:CYP stock, check out TipRanks’ Stock Analysis page.
